Article
Combination of artesunate and ruxolitinib inhibits T-lymphoblastic leukemia/lymphoma proliferation via the Janus kinase/signal transducer and activator of transcription pathway
2025-09-25
Abstract excerpt
<title>Abstract</title> <p>BACKGROUND T-lymphoblastic leukemia/lymphoma is a highly aggressive malignancy, and its prognosis after relapse is poor, with a 5-year overall survival rate of 35%. Mutations in the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway are the second most common mutation type in T-lymphoblastic leukemia/lymphoma, and hyperactivation of this pathway can promote...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 7050241a-f7a8-5d71-ac2c-bc4d68a68342
- DOI
- 10.21203/rs.3.rs-7241143/v1
